inclusive. Characteristics of NICU admitted and non-admitted liveborn babies were compared. Modelling was based on increased livebirth and NICU admission assuming conditions equivalent to that of babies born at 25 weeks.
Royal North Shore Hospital Background: There is a lack of evidence around the risk of transfusion following vaginal birth after caesarean (VBAC) compared to elective repeat caesarean section (ERCS); this is important for decision-making about birth options.
Aim(s)/objective(s):
To determine blood transfusion rates and risk of transfusion following intended VBAC and ERCS.
Method/approach: Women with a prior primary caesarean who had a subsequent birth at term (> = 37 weeks) in NSW, 2000-2012, were identified from the NSW Perinatal Data Collection. Red cell transfusions were identified from linked hospital records. Women deemed ineligible for VBAC were excluded. Logistic regression was used to determine the risk of transfusion associated with intended VBAC compared to ERCS. Intended mode of delivery was classified as follows: 1) intended VBAC and vaginal birth, 2) intended VBAC and caesarean birth, 3) intended ERCS, and 4) 'intention uncertain'.
Results/findings: 90,439 women birthing following prior primary caesarean were identified. Rates of blood transfusion were: 1.4% for intended VBAC and vaginal delivery (n = 17,849), 1.2% for intended VBAC and caesarean delivery (n = 7,648), 0.3% for intended ERCS (n = 60,471), and 1.1% for 'intention uncertain' (n = 4,471). After adjusting for maternal and pregnancy characteristics, the odds of transfusion were four times higher for women classified as intended VBAC compared to intended ERCS (OR = 4.14, 95% CI: 3.39-5.05).
Discussion/Conclusions: Following a prior primary caesarean section, there was a higher risk of blood transfusion associated with attempting VBAC compared to ERCS. Though the risk is small, it is important women considering VBAC choose birthing facilities with ready access to blood products. Background: Babies born after FGR have reduced myelination and are at increased risk for cerebral palsy (CP). We propose that decreased monocarboxylate transporter-8 (MCT8) leads to decreased thyroid hormone (TH) uptake in the FGR brain, causing reduced myelination. We determined if the TH analogue, diiodothyropropionic acid (DITPA), that works independent of MCT8, could restore myelination after FGR.
Methods: At day 18 of pregnancy (term = 22 days), rats underwent bilateral uterine vessel ligation or sham surgery to generate FGR (n = 12 litters) and control (n = 8 litters) pups. At postnatal (P) days 7 and 14, brains were assessed for density of myelinated (MBP + ve) fibres and mature (CC1 + ve) oligodendrocytes, and gene expression of MCT8 and TH receptor-alpha (TR-alpha). A second cohort of control (n = 21 litters) and FGR (n = 25 litters) pups was treated with DITPA (0.5 mg/100 g; I.P.) from P1-6, and at P7 body composition and cerebral myelination assessed.
Results: In FGR vs control pups there was a significant decrease in i) body weight (P7), ii) fat and lean mass (P7), iii) MBP + ve fibres (P7, P14) and CC1 + ve oligodendrocytes (P14) in the corpus callosum and external capsule, and iv) MCT8 and TR-alpha mRNA levels (P7) in white matter. DITPA treatment in FGR pups did not affect body weight, lean and fat mass, or bone mineral content or composition, but restored myelination at P7.
Conclusion: TH signalling, crucial for developmental myelination, is reduced in the postnatal FGR brain. DITPA has the potential to promote myelination in FGR infants at risk of white matter injury and CP. 
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